Finance

Lists
002294:SHE
Shenzhen Salubris Pharmaceuticals Co Ltd
CN¥31,03
+1,97%
(+0,60) 1D
15 Okt., 10:46:27 GMT+8  ·   CNY
All symbols
SymbolPriceChange% Change
Generating top insights for 002294...
Open
CN¥30,02
High
CN¥31,50
Low
CN¥29,91
Mkt. cap
33,85 mjd
Avg. vol.
9,32 m
Volume
11,01 m
Dividend
1,77%
Quarterly dividend
CN¥0,14
Ex-dividend date
26 Mei 2026
P/E ratio
51,36
52-wk high
CN¥70,99
52-wk low
CN¥29,25
EPS
CN¥0,60
Shares outstanding
1,11 mjd
No. of employees
4 k
Open
CN¥30,02
High
CN¥31,50
Low
CN¥29,91
Mkt. cap
33,85 mjd
Avg. vol.
9,32 m
Volume
11,01 m
Dividend
1,77%
Quarterly dividend
CN¥0,14
Ex-dividend date
26 Mei 2026
P/E ratio
51,36
52-wk high
CN¥70,99
52-wk low
CN¥29,25
EPS
CN¥0,60
Shares outstanding
1,11 mjd
No. of employees
4 k
News stories
From web sources and news partners
The Daily News | Texas' Oldest Newspaper
The Daily News | Texas' Oldest Newspaper
·
17 minute gelede
FILE PHOTO: SK Hynix at the Nasdaq market in New York
The Globe and Mail
The Globe and Mail
·
35 minute gelede
U.S. Analyst Updates: October 14th, 2026
Profile
Shenzhen Salubris Pharmaceuticals is a Chinese pharmaceutical company. Founded in November 1998 and based in Shenzhen, it has a market cap of US$4.4 billion, 3,121 employees and annual sales of $553 million as of 2019. Shenzhen Salubris is headed by the billionaire Ye Chenghai. Wikipedia
About Shenzhen Salubris Pharmaceuticals Co Ltd
CEO-
Employees4,09 k
Founded03 Nov. 1998
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
1,11 mjd
1,11 mjd
1,23 mjd
1,25 mjd
Cost of goods sold
279,29 m
302,88 m
287,67 m
343,20 m
Cost of revenue
279,29 m
302,88 m
287,67 m
343,20 m
Research and development expenses
127,63 m
176,44 m
131,32 m
139,63 m
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
486,77 m
568,30 m
551,61 m
596,71 m
Operating expense
595,66 m
770,11 m
694,36 m
749,18 m
Total operating expenses
874,96 m
1,07 mjd
982,03 m
1,09 mjd
Operating income
235,37 m
38,38 m
246,41 m
158,32 m
Other non operating income
-14,62 m
13,83 m
-5,27 m
5,40 m
EBT including unusual items
234,09 m
5,21 m
255,47 m
142,37 m
EBT excluding unusual items
246,15 m
72,00 m
252,02 m
160,96 m
Income tax expense
18,06 m
-56,18 m
29,65 m
-22,28 m
Effective tax rate
7,72%
-1 078,48%
11,60%
-15,65%
Other operating expenses
-17,83 m
34,11 m
9,61 m
16,33 m
Net income
215,63 m
70,80 m
225,27 m
161,82 m
Net profit margin
19,42%
6,37%
18,34%
12,94%
Earnings per share
-
-
-
-
Interest and investment income
26,87 m
37,76 m
15,05 m
12,29 m
Interest expense
-4,88 m
-7,50 m
-4,17 m
-4,97 m
Net interest expenses
22,00 m
30,27 m
10,88 m
7,32 m
Depreciation and amortization charges
-
-
-
-
EBITDA
325,52 m
135,48 m
343,52 m
257,90 m
Gain or loss from assets sale
-983,77 k
3,03 m
-
166,24 k
AI content may include mistakes. Learn more
Google-programme